<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04153136</url>
  </required_header>
  <id_info>
    <org_study_id>MGH2019P002355</org_study_id>
    <nct_id>NCT04153136</nct_id>
  </id_info>
  <brief_title>Effects of Sacubitril/Valsartan on Subclinical Heart Failure in HIV (The ENCHANTMENT HIV Study)</brief_title>
  <official_title>Ending Subclinical Heart Failure Using an Aldosterone and Natriuretic Peptide Targeted Treatment in HIV--The ENCHANTMENT HIV Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Persons with HIV, even those well-treated, are at increased risk for heart disease when
      compared to the general population. Two hormones called aldosterone and brain natriuretic
      peptide (BNP), which have been shown to be abnormal in HIV, may be associated with
      inflammation as well as early changes in structure and function of the heart. This study is
      being conducted to evaluate whether therapies to block aldosterone and increase BNP levels
      may reduce the burden and progression of heart failure to improve cardiovascular health.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 6-month study enrolling persons with HIV with no known history of heart disease.
      Participants will be screened for early signs of heart failure using cardiac ultrasound
      (cardiac transthoracic echocardiography or cardiac TTE). Those participants who have early
      changes in the structure and function of the heart and may be at future risk for heart
      failure will be enrolled into the study. Additional imaging of the heart will occur using
      cardiac magnetic resonance imaging (cardiac MRI). Following baseline studies, participants
      will either receive a medication called sacubitril/valsartan or placebo for 6 months.
      Sacubitril/valsartan in an FDA approved medication currently being used for heart failure
      with reduced ejection fraction in the general population, and we are evaluating whether this
      medication could be useful to reduce HIV-related heart failure with preserved ejection
      fraction. Sacubitril/valsartan is an oral medication taken twice daily that may block
      aldosterone hormone and increase natriuretic peptide hormone. Overall, this study aims to
      investigate the effect of sacubitril/valsartan on measures of heart disease related to
      inflammation, structure and function of the heart muscle in HIV using cardiac TTE and cardiac
      MRI imaging as well as blood markers of heart failure and inflammation.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">February 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial Inflammation/Fibrosis</measure>
    <time_frame>6 months</time_frame>
    <description>Myocardial Inflammation/Fibrosis measured by extracellular volume fraction via cardiac magnetic resonance imaging</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left Atrial Volume Index</measure>
    <time_frame>6 months</time_frame>
    <description>Left Atrial Volume Index measured by cardiac transthoracic echocardiography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Indices of Myocardial Dysfunction</measure>
    <time_frame>6 months</time_frame>
    <description>Alterations in other cardiac structure and function as measured by cardiac magnetic resonance imaging or cardiac transthoracic echocardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of Myocardial Inflammation and Fibrosis</measure>
    <time_frame>6 months</time_frame>
    <description>Circulating biomarkers of myocardial inflammation and fibrosis: Gal3, ST2, GDF15, hs-cTnT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Natriuretic Peptides</measure>
    <time_frame>6 months</time_frame>
    <description>Circulating cardiac natriuretic peptides: ANP, BNP, NT-proBNP</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>HIV/AIDS</condition>
  <condition>Heart Failure With Preserved Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>Sacubitril/Valsartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sacubitril/Valsartan 49-51mg twice daily along with lifestyle modification (counseling regarding diet and healthy activity) for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo twice daily along with lifestyle modification (counseling regarding diet and healthy activity) for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sacubitril-Valsartan 49-51Mg Oral Tablet</intervention_name>
    <description>By mouth twice daily</description>
    <arm_group_label>Sacubitril/Valsartan</arm_group_label>
    <other_name>Entresto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Placebo oral tablet By mouth twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Antiretroviral therapy use for &gt;12 months

          2. HIV Viral Load &lt;200 copies/mL

          3. Increased waist circumference based on NCEP criteria (male&gt;102cm2 and female&gt;88cm2) or
             increased waist to hip ratio based on WHO criteria (male&gt;0.95 and female&gt;0.80)

          4. Left Ventricular Ejection Fraction&gt;50%

          5. Demonstration of one or more criteria for myocardial dysfunction on cardiac
             transthoracic echocardiogram, relevant to the progression of heart failure with
             preserved ejection fraction:

               -  Left Atrial Volume Index &gt; 28 mL/m2

               -  Global Longitudinal Strain &lt;18%

               -  Left Ventricular Mass Index &gt; 95g/m2 (female), 115 g/m2 (male)

        Exclusion Criteria:

          1. Known history of congestive heart failure or valvular disease

          2. Recent cardiac event or stroke within 3 months

          3. Current medication use acting along the RAAS pathway (ACEi, ARB, MR blockade, direct
             renin inhibitor), potassium (K) supplementation or diuretic

          4. Angioedema to ACEi or ARB

          5. SBP&lt;100 mmHg

          6. Medication suspected to have contraindication with active study drug

          7. Steroid use within last 3 months

          8. Uncontrolled diabetes requiring insulin and/or HbA1c &gt; 7.5%

          9. Creatinine (Cr)&gt;1.5 mg/dL and estimated GFR&lt;60 mL/min/1.73m2

         10. K&gt;5.5 mEq/L

         11. Hemoglobin &lt;10.0 g/dL

         12. Known liver disease or ALT&gt;3x upper limit normal

         13. Pregnant, actively seeking pregnancy or breastfeeding

         14. Estrogen, progestin derivative, or other sex steroid use within 3 months. Stable
             physiologic testosterone replacement (&gt; 3 months) is acceptable

         15. Current bacterial or other infection

         16. Active substance abuse

         17. Known reaction to gadolinium
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Suman Srinivasa, MD, MS</last_name>
    <phone>6177269109</phone>
    <email>ssrinivasa@mgh.harvard.edu</email>
  </overall_contact>
  <reference>
    <citation>Srinivasa S, Fitch KV, Wong K, Torriani M, Mayhew C, Stanley T, Lo J, Adler GK, Grinspoon SK. RAAS Activation Is Associated With Visceral Adiposity and Insulin Resistance Among HIV-infected Patients. J Clin Endocrinol Metab. 2015 Aug;100(8):2873-82. doi: 10.1210/jc.2015-1461. Epub 2015 Jun 18.</citation>
    <PMID>26086328</PMID>
  </reference>
  <reference>
    <citation>Murphy CA, Fitch KV, Feldpausch M, Maehler P, Wong K, Torriani M, Adler GK, Grinspoon SK, Srinivasa S. Excessive Adiposity and Metabolic Dysfunction Relate to Reduced Natriuretic Peptide During RAAS Activation in HIV. J Clin Endocrinol Metab. 2018 Apr 1;103(4):1558-1565. doi: 10.1210/jc.2017-02198.</citation>
    <PMID>29408981</PMID>
  </reference>
  <reference>
    <citation>Srinivasa S, Fitch KV, Wong K, O'Malley TK, Maehler P, Branch KL, Looby SE, Burdo TH, Martinez-Salazar EL, Torriani M, Lyons SH, Weiss J, Feldpausch M, Stanley TL, Adler GK, Grinspoon SK. Randomized, Placebo-Controlled Trial to Evaluate Effects of Eplerenone on Metabolic and Inflammatory Indices in HIV. J Clin Endocrinol Metab. 2018 Jun 1;103(6):2376-2384. doi: 10.1210/jc.2018-00330.</citation>
    <PMID>29659888</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 30, 2019</study_first_submitted>
  <study_first_submitted_qc>November 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2019</study_first_posted>
  <last_update_submitted>April 10, 2020</last_update_submitted>
  <last_update_submitted_qc>April 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Suman Srinivasa, M.D.</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Sacubitril/valsartan</keyword>
  <keyword>Heart Failure with Preserved Ejection Fraction</keyword>
  <keyword>Aldosterone</keyword>
  <keyword>Natriuretic Peptides</keyword>
  <keyword>Myocardial Dysfunction</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>LCZ 696</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

